Compare Tencent Music Entertainment Group - ADR (TME) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tencent Music Entertainment Group - ADR vs Zimmer Biomet Holdings Inc — how do they compare? Tencent Music Entertainment Group - ADR trades at $8.38 (market cap $12.83B), while Zimmer Biomet Holdings Inc trades at $89.91 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is the larger of the two by market cap, and Tencent Music Entertainment Group - ADR pays the higher dividend (3.02%). Which is the better fit depends on your goals — on Pluang, investors hold Tencent Music Entertainment Group - ADR for 67 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| TME | ZBH | |
|---|---|---|
Market Cap | $12.83B | $16.95B |
Volume | 3,618,478 | 2,505,240 |
Sector | Media | Health |
52-Week High | $23.71 | $103.98 |
52-Week Low | $7.74 | $79.58 |
Typical Hold Time | 67 Days | 89 Days |
Enterprise Value | $10.77B | $24.02B |
Dividend Yield | 3.02% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tencent Music Entertainment (TME) trades at $8.38, up 4.88% today, but technical indicators signal a bearish trend with moving averages and ADX suggesting selling pressure. Fundamentally, the company shows strong profitability with 26.28% net margin and attractive valuation at 9.33 P/E ratio. Recent Q2 2026 earnings beat expectations with $0.25 EPS, though revenue growth remains modest. The company recently completed a $1 billion notes offering to strengthen its financial position.
TME presents a compelling value opportunity with discounted valuation metrics and solid profitability, though facing competitive pressures from ByteDance's Soda Music. Analyst consensus leans neutral with $12.50 price target representing 49% upside potential. Key risks include user churn among casual listeners and rising operating expenses needed to retain users in the competitive music streaming landscape.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
